WESTMINSTER, Colo., Aug. 3, 2015 (GLOBE NEWSWIRE) -- Despite warnings from scientists who have shown unquestionable data that Earth climate has been changing due to human activities, governments and multinational corporations for years have denied scientific evidences. MAP infection in cattle draws many similarities with global warming. Despite the fact that MAP has been linked to several human diseases, governments, the cattle and dairy industry have continued to ignore scientific data and have not implemented any credible programs to control MAP infection. In the meantime, herd prevalence of MAP infection in cattle worldwide has reached alarming levels. More than 90% of dairy herds in the US are infected. In the UK, 50% of dairy herds are infected with MAP. A recent report from the Advisory Committee on Dangerous Pathogens (ACDP), a scientific advisory board of the UK Government, concluded that MAP potential for human infection exist and is not limited to Chron's Disease (CD). The ACDP report points out that genome analysis have suggested an association between MAP and several other inflammatory diseases besides CD. These diseases are:

  • Irritable Bowel Syndrome 

  • Type 1 Diabetes Mellitus 

  • Multiple Sclerosis 

  • Parkinson's Disease 

  • Autism 

The ACDP reports concluded that "it is therefore possible that human effects of MAP exposure and infection extend beyond just CD." Additionally, the ACDP report states "with the advent of new and improved methods to detect viable MAP in milk and dairy products, there is new evidence of higher levels of viable MAP than previously believed in processed dairy products, in particular, in infant milk which is consumed by the most susceptible sector of the population." 

Dr. Tony Milici, Chairman & CEO of GeneThera (OTC: GTHR) commented "It is quite clear from the ACDP report and a large number of studies that the risk of MAP contamination of milk and dairy products poses to the general population; particularly, children and young adults, it can no longer be underestimated. Dairies and baby formula producers need to implement large scale testing programs to control MAP contamination in milk and certify that MAP-free milk is used for baby food production."

GeneThera has spent several years developing state-of-the-art technology to test milk products using advanced integrated laboratory robotic platforms that allow the detection of Mycobacterium Paratuberculosis in a highly sensitive and fast process. A single integrated robotic system is capable to process over two thousand samples daily with minimum human intervention. This automated platform provides GeneThera with a standardized system that can be serially duplicated, readily deployed, and supported across the globe to meet the growing needs of the worldwide dairy industry. By standardizing on a flexible, easy to use robotic platform, GeneThera will be able to meet its goals of building a global network of labs that will test and communicate results to food producers in real time, improving animal health and food safety.

About GeneThera, Inc.

GeneThera, Inc. is a molecular biotechnology company located in Westminster, Colorado. The Company's proprietary diagnostic solution is based on a genetic expression assay, GES and Johne's disease management system, HERDCHECK™, designed to function on a highly automated PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GES and HERDCHECK™ systems are designed for a host of individual diseases, the current priority being Johne's disease.

This press release contains forward-looking statements, which are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "intends," "believes," and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company's filings with the Securities and Exchange Commission. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.

CONTACT: Tony Milici MD, Ph.D. GeneThera Inc. 303 439-2085Source:GeneThera